Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Holland C. Detke, Brian A. Millen, Qi Zhang, et al.
Headache The Journal of Head and Face Pain (2019) Vol. 60, Iss. 2, pp. 348-359
Open Access | Times Cited: 49

Showing 26-50 of 49 citing articles:

Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study
Claudia Altamura, Sabina Cevoli, Cinzia Aurilia, et al.
Neurological Sciences (2020) Vol. 41, Iss. 12, pp. 3385-3389
Open Access | Times Cited: 13
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis
Patricia Pozo‐Rosich, Karen Samaan, Todd J. Schwedt, et al.
Advances in Therapy (2021) Vol. 38, Iss. 6, pp. 3154-3165
Open Access | Times Cited: 10
Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
Samuel Díaz Insa, Ángel Luis Guerrero Peral, J. Viguera Romero, et al.
Pain and Therapy (2024) Vol. 13, Iss. 3, pp. 557-576
Open Access | Times Cited: 1
OnabotulinumtoxinA injection in the treatment of chronic migraine
Yen-Feng Wang
Progress in brain research (2020), pp. 171-206
Closed Access | Times Cited: 9
Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
Hisaka Igarashi, Mamoru Shibata, Akichika Ozeki, et al.
Journal of Pain Research (2021) Vol. Volume 14, pp. 3555-3564
Open Access | Times Cited: 8
Atogepant for the prevention of episodic migraine in adults
Maranda Paige Switzer, Joseph E. Robinson, Kayla Rena Joyner, et al.
SAGE Open Medicine (2022) Vol. 10
Open Access | Times Cited: 5
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, et al.
Brain and Behavior (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 4
The Pharmacokinetics of Drug Delivery to the Upper Nasal Space: A Review of INP105 Development
Stephen B. Shrewsbury, G. A. L. Davies, Lisa A. McConnachie, et al.
Medical Research Archives (2022) Vol. 10, Iss. 9
Open Access | Times Cited: 4
The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
Panagiotis Gklinos, Dimos D. Mitsikostas
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 245-245
Open Access | Times Cited: 4
Comparison of Early-onset Efficacy of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies for Patients with Migraine in Real-world Clinical Practice: Study Protocol for an Exploratory Clinical Trial
Takafumi Tanei, Satoshi Maesawa, Yusuke Nishimura, et al.
Neurologia medico-chirurgica (2024)
Open Access
Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine
Nicola Giffin
Practical Neurology (2023) Vol. 23, Iss. 3, pp. 200-207
Closed Access | Times Cited: 1
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
The importance of an early onset of migraine preventive disease control: A roundtable discussion
Christopher Gottschalk, Anirban Basu, Andrew Blumenfeld, et al.
Cephalalgia Reports (2022) Vol. 5, pp. 251581632211345-251581632211345
Open Access | Times Cited: 2
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 9, pp. 893-904
Closed Access | Times Cited: 2
Galcanezumab
Uwe Reuter, Bianca Raffaelli
Headache (2021), pp. 99-108
Closed Access | Times Cited: 1
Anwendung monoklonaler Antikörper zur Migräneprophylaxe in der Praxis
Ruth Ruscheweyh, Hans‐Christoph Diener
InFo Neurologie + Psychiatrie (2023) Vol. 25, Iss. 3, pp. 30-39
Closed Access
Novel migraine treatment with CGRP-related monoclonal antibodies
Mamoru Shibata
Rinsho Shinkeigaku (2020) Vol. 60, Iss. 10, pp. 668-676
Open Access
Galcanezumab (Emgality)
Reimbursement Team
Canadian Journal of Health Technologies (2022) Vol. 2, Iss. 1
Open Access
Galcanezumab (Emgality)
Reimbursement Team
Canadian Journal of Health Technologies (2022) Vol. 2, Iss. 3
Open Access
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Gabriel Taricani Kubota
Arquivos de Neuro-Psiquiatria (2022) Vol. 80, Iss. 5 suppl 1, pp. 218-226
Open Access
3º CONGRESSO INTERDISCIPLINAR DA ÁREA MÉDICA
Revista Recima
RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 (2022) Vol. 3, Iss. 1, pp. e3122557-e3122557
Open Access
Neues in der Migränetherapie
Ruth Ruscheweyh, Jan Hoffmann
Nervenheilkunde (2021) Vol. 40, Iss. 03, pp. 140-148
Closed Access
The Knowledge of Headache Treatment
Daisuke Danno
Japanese Journal of Neurosurgery (2021) Vol. 30, Iss. 12, pp. 828-835
Open Access
Migraine Therapy: New Horizons and Beyond
Mamoru Shibata
Nihon Naika Gakkai Zasshi (2021) Vol. 110, Iss. 11, pp. 2449-2457
Open Access
Previous Page - Page 2

Scroll to top